Drug intelligence / Profile preview

BG-2201

Development stage: Preclinical
Lead developer: Guangzhou Bio-gene Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BG-2201 is an autologous CAR-T cell therapy under preclinical development by Guangzhou Bio-gene Technology. It is being investigated primarily for the treatment of neoplasms, with a focus on acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The drug utilizes chimeric antigen receptor T-cell technology to target malignant cells in hematologic cancers. As of March 2025, its highest development status is preclinical, and it has not received regulatory approval in any country[1][2].

Targets

BCMA (B-cell maturation antigen)GPRC5D

Beyond the preview

Go deeper on BG-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-2201.

Explore the full profile